Endometrial cancer(EC)stands as one of the most prevalent gynecological malignancies affecting women,with its incidence and disease-related mortality steadily on the rise.Disulfiram(DSF),an FDA-approved medication pri...Endometrial cancer(EC)stands as one of the most prevalent gynecological malignancies affecting women,with its incidence and disease-related mortality steadily on the rise.Disulfiram(DSF),an FDA-approved medication primarily used for treating alcohol addiction,has exhibited promising anti-tumor properties.Studies have revealed DSF’s capacity for enhanced anti-tumor activity,particularly when combined with copper.The novel Copper-Cysteamine(CuCy)compound,Cu_(3)Cl(SR)_(2)(R--CH_(2)CH_(2)NH_(2)),showcases photodynamic effects and demonstrates significant anti-tumor potential under various conditions,including exposure to ultraviolet light,X-ray,microwave,and ultrasound.This study delves into exploring the synergistic anti-tumor effects and underlying mechanisms by utilizing copper-cysteamine in conjunction with DSF against endometrial cancer.The investigation involved comprehensive analyses encompassing in vitro experiments utilizing Ishikawa cells,in vivo studies,and transcriptomic analyses.Remarkably,the combined administration of both compounds at a low dose of 0.5μM exhibited pronounced efficacy in impeding tumor growth,inhibiting blood vessel formation,and stimulating cell apoptosis.Notably,experiments involving transplanted tumors in nude mice vividly demonstrated the significant in vivo anti-tumor effects of this combination treatment.Detailed examination through transmission electron microscopy unveiled compelling evidence of mitochondrial damage,cellular swelling,and rupture,indicative of apoptotic changes in morphology due to the combined treatment.Moreover,transcriptomic analysis unveiled substantial downregulation of mitochondrial-related genes at the molecular level,coupled with a significant hindrance in the DNA repair pathway.These findings strongly suggest that the combined application of CuCy and DSF induces mitochondrial impairment in Ishikawa cells,thereby fostering apoptosis and ultimately yielding potent anti-tumor effects.展开更多
基金supported by the National Natural Science Foundation of China(22071066)CAMS Innovation Fund for Medical Science(CIFMS,No.2018-12M-1-004)the project from department of Education,Jiangsu Province for the School of CHIPS at XJTLU(EFP10120240023).
文摘Endometrial cancer(EC)stands as one of the most prevalent gynecological malignancies affecting women,with its incidence and disease-related mortality steadily on the rise.Disulfiram(DSF),an FDA-approved medication primarily used for treating alcohol addiction,has exhibited promising anti-tumor properties.Studies have revealed DSF’s capacity for enhanced anti-tumor activity,particularly when combined with copper.The novel Copper-Cysteamine(CuCy)compound,Cu_(3)Cl(SR)_(2)(R--CH_(2)CH_(2)NH_(2)),showcases photodynamic effects and demonstrates significant anti-tumor potential under various conditions,including exposure to ultraviolet light,X-ray,microwave,and ultrasound.This study delves into exploring the synergistic anti-tumor effects and underlying mechanisms by utilizing copper-cysteamine in conjunction with DSF against endometrial cancer.The investigation involved comprehensive analyses encompassing in vitro experiments utilizing Ishikawa cells,in vivo studies,and transcriptomic analyses.Remarkably,the combined administration of both compounds at a low dose of 0.5μM exhibited pronounced efficacy in impeding tumor growth,inhibiting blood vessel formation,and stimulating cell apoptosis.Notably,experiments involving transplanted tumors in nude mice vividly demonstrated the significant in vivo anti-tumor effects of this combination treatment.Detailed examination through transmission electron microscopy unveiled compelling evidence of mitochondrial damage,cellular swelling,and rupture,indicative of apoptotic changes in morphology due to the combined treatment.Moreover,transcriptomic analysis unveiled substantial downregulation of mitochondrial-related genes at the molecular level,coupled with a significant hindrance in the DNA repair pathway.These findings strongly suggest that the combined application of CuCy and DSF induces mitochondrial impairment in Ishikawa cells,thereby fostering apoptosis and ultimately yielding potent anti-tumor effects.
